Research Output per year
Fingerprint Dive into the research topics where Matthew S Block is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 5 Similar Profiles
Ovarian Neoplasms
Medicine & Life Sciences
Melanoma
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Survival
Medicine & Life Sciences
T-Lymphocytes
Medicine & Life Sciences
Immunotherapy
Medicine & Life Sciences
Recurrence
Medicine & Life Sciences
Biomarkers
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1996 2019
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1
Block, M. S., Nevala, W. K., Pang, Y. P., Allred, J. B., Strand, C. & Markovic, S. N., Aug 1 2019, In : Melanoma research. 29, 4, p. 420-427 8 p.Research output: Contribution to journal › Article
resiquimod
Melanoma
Vaccines
Clinical Trials
Appointments and Schedules
2
Citations
(Scopus)
Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine
Vera, J., Paludo, J., Kottschade, L., Brandt, J., Yan, Y., Block, M. S., Mc Williams, R. R., Dronca, R. S., Loprinzi, C. L., Grothey, A. F. & Markovic, S. N., Jan 1 2019, In : Supportive Care in Cancer.Research output: Contribution to journal › Article
Colchicine
Fever
Mitogen-Activated Protein Kinases
Familial Mediterranean Fever
Therapeutics
6
Citations
(Scopus)
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M. S. & Kudva, Y. C., Feb 1 2019, In : BMJ Open Diabetes Research and Care. 7, 1, e000591.Research output: Contribution to journal › Article
Insulin
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Programmed Cell Death 1 Receptor
Diabetic Ketoacidosis
3
Citations
(Scopus)
The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy
Cannon, M. J., Block, M. S., Morehead, L. C. & Knutson, K. L., Feb 1 2019, In : Immunotherapy. 11, 2, p. 75-79 5 p.Research output: Contribution to journal › Comment/debate
Cancer Vaccines
Glioblastoma
Pancreatic Neoplasms
Acute Myeloid Leukemia
Ovarian Neoplasms
The role of serum lactate dehydrogenase level as a prognostic indicator in resected, high risk melanoma
Kumar, A. B., Aguilera, J. V., Velazquez, A., Yan, Y., Jakub, J. W., Brewer, J., Hieken, T. J., Block, M. S., Mc Williams, R. R., Otley, C., Markovic, S. N. & Kottschade, L., Jan 1 2019, In : Dermatologic Therapy. e12813.Research output: Contribution to journal › Letter
L-Lactate Dehydrogenase
Melanoma
Serum